胸腺肽联合洛铂对肺癌恶性胸腔积液患者的疗效和血清炎性因子及T淋巴细胞的影响

Curative Effect of Thymic Peptide Combined with Lobaplatin in Patients with Malignant Pleural Effusion of Lung Cancer and Effect on the Serum Inflammatory Factor and T Lymphocytes

目的探讨胸腺肽联合洛铂对肺癌恶性胸腔积液患者的疗效和血清炎性因子及T淋巴细胞的影响。方法选择2016年2月—2017年11月该院收治的肺癌恶性胸腔积液患者为临床研究对象。使用计算机随机分组的方法进行分组,每组35例。所有患者均使用B超进行胸部定位,并在局麻状态下使用中心静脉导管做胸腔穿刺,对照组在引流完成后使用洛铂干预,实验组在对照组治疗的基础上给予胸腺肽联合洛铂,观察比较两组患者的疗效、血清炎性因子和T淋巴细胞。结果实验组肺癌恶性胸腔积液患者35例,完全缓解21例,部分缓解11例,无效3例;对照组完全缓解11例,部分缓解14例,无效10例。实验组疗效明显优于对照组,差异有统计学意义(P<0.05)。实验组治疗后TNF-α、IL-18、CD8+分别为(34.22±5.45)pg/mL、(146.46±18.55)ng/L、(51.78±5.44)%,低于对照组(45.64±7.75)pg/mL、(164.86±19.08)ng/L、(57.86±5.68)%,(t=6.303、8.403、6.493,P<0.05);实验组治疗后CD3+、CD4+分别为(60.33±4.87)%、(45.68±5.97)%,高于对照组(54.88±3.97)%、(40.07±6.13)%,差异有统计学意义(t=5.394、4.302,P<0.05)。结论胸腺肽联合洛铂对肺癌恶性胸腔积液的效果较好,值得应用。

Objective To study the curative effect of thymic peptide combined with lobaplatin in patients with malignant pleural effusion of lung cancer and effect on the serum inflammatory factor and T lymphocytes. Methods 70 cases of patients with malignant pleural effusion of lung cancer admitted and treated in our hospital from February 2016 to November 2017 were selected and randomly divided into two groups with 35 cases in each, all patients used the ultrasound B for chest positioning, and the patients used the central venous catheter for thoracentesis under the local anesthesia, while the control group used the lobaplatin for intervention on the basis of the control group, and the curative effect, serum inflammatory factor and T lymphocytes were observed and compared. Results In the experimental group,there were 35 cases with malignant pleural effusion of lung cancer, 21 cases were totally relived, 11 cases were partially relieved, 3 cases were ineffective, and in the control group, 11 cases were totally relieved, 14 cases were partially relieved, and 10 cases were ineffective, and the curative effect in the experimental group was obviously better than that in the control group, and the difference was statistically significant（P〈0.05）, and the TNF-α, IL-18, CD8＋ in the experimental group after treatment were lower than those in the control group [（34.22 ±5.45）pg/mL,（146.46 ±18.55）ng/L,（51.78±5.44）% vs（45.64±7.75）pg/mL,（164.86±19.08）ng/L,（57.86±5.68）%]（t=6.303, 8.403, 6.493, P〈0.05）, after treatment, the CD3＋, CD4 ＋ in the experimental group were higher than those in the control group [（60.33 ±4.87）%,（45.68±5.97）% vs（54.88±3.97）%,（40.07±6.13）%], and the differences were statistically significant（t=5.394, 4.302,P〈0.05）. Conclusion The effect of thymic peptide combined with lobaplatin in patients with malignant pleural effusion of lung cancer is better, which is worth application.